Navigation Links
CryoCor Announces Web cast and Conference Call of 2007 Year End Results
Date:3/14/2008

SAN DIEGO, March 14 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today that it will release its financial results for the year ended December 31, 2007 on Thursday, March 20, 2008 after the close of the U.S. financial markets.

CryoCor will also hold a Web cast and conference call at 5:00 p.m. ET / 2:00 p.m. PT on March 20, 2008. Management will discuss the financial results, provide an update on the commercialization of the Company's Cardiac Cryoablation System for the treatment of right atrial flutter and discuss the Company's strategic objectives for 2008.

The dial-in numbers are 1-877-407-4018 for domestic callers and 1-201-689-8471 for international callers. A live Web cast of the conference call will be available online from the investor relations page of the Company's corporate Web site at http://www.cryocor.com.

After the live Web cast, the call will remain available on CryoCor's Web site for at least 30 days following presentation. In addition, a telephonic replay of the call will be available. The replay dial-in numbers are 1-877-660-6853 for domestic callers 1-201-612-7415 for international callers. Please use account number 3055 and conference ID number 278655.

About CryoCor

CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com.

Contacts:

CryoCor The Ruth Group

Gregory J. Tibbitts Nick Laudico / Zack Kubow (investors)

Chief Financial Officer (646) 536-7030 / 7020

(858) 909-2200 nlaudico@theruthgroup.com

gtibbitts@cryocor.com zkubow@theruthgroup.com

Jason Rando (media)

(646) 536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE CryoCor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CryoCor to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
2. Dr. Warren Jackman Joins CryoCor Scientific Advisory Board
3. CryoCath intends to contest patent infringement claim by CryoCor, Inc.
4. CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation
5. CryoCor Files Response to Patent Infringement Lawsuit
6. CryoCor Announces Web cast and Conference Call of Third Quarter 2007 Results
7. CryoCor Appoints New Vice President of Sales and Marketing
8. CryoCor to Present at Maxim Group First Annual Growth Conference in New York
9. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
10. Swiss Systems Biology Initiative announces Flagship Projects
11. Plexus Systems, Inc. Announces Participation at AM EXPO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
Breaking Medicine Technology: